Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
Reshef A, Hsu C, Katelaris CH, Li PH, Magerl M, Yamagami K, Guilarte M, Keith PK, Bernstein JA, Lawo JP, Shetty H, Pollen M, Wieman L, Craig TJ; VANGUARD Study Group.
Reshef A, et al. Among authors: yamagami k.
Allergy. 2024 Oct 7. doi: 10.1111/all.16351. Online ahead of print.
Allergy. 2024.
PMID: 39370961